5 Key Takeaways
-
1
Recent advances in biointerventional technology enable surgeons to enhance both trabecular and uveoscleral drainage pathways for glaucoma management.
-
2
The AlloFlo Uveo device is the first commercially available solution for surgical uveoscleral enhancement, expanding treatment options for glaucoma.
-
3
Patient education is crucial, framing surgery as a proactive tool for vision preservation rather than a last resort in glaucoma care.
-
4
Research shows biointerventional uveoscleral surgery significantly reduces intraocular pressure and medication requirements with a strong safety profile.
-
5
Uveoscleral enhancement procedures offer economic advantages, potentially generating substantial additional revenue for practices performing MIGS.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.